Phaseline

Companies › Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals: clinical trials, targets and expected readouts

9 active drug programs in 13 registered trials: 6 Phase 1, 6 Phase 3, 1 Phase 2; Metabolic and endocrine, Neurology, Ophthalmology, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zodasiran
ANGPTL3 antisense oligonucleotide
ANGPTL3Phase 3Homozygous Familial HypercholesterolemiaAug 2027
Plozasiran
APOC3 antisense oligonucleotide
APOC3Phase 3Severe Hypertriglyceridemia; HypertriglyceridemiaJul 2028
ARO-RAGE
RAGE antagonist / inhibitor
AGERPhase 2AsthmaDec 2027
ARO-ATXN2 Injection
Antisense oligonucleotide targeting ATXN2 mRNA
ATXN2Phase 1Spinocerebellar Ataxia Type 2Dec 2026
ARO-ALK7
ALK7 activator (activin receptor-like kinase 7 agonist)
ALK7Phase 1ObesityFeb 2027
ARO-MAPT-SC
Antisense oligonucleotide targeting MAPT mRNA for reduction of tau protein
MAPTPhase 1Alzheimer DiseaseJun 2027
ARO-DIMERPA
Antisense oligonucleotide (ASO) targeting apolipoprotein B mRNA
APOBPhase 1Hyperlipidemia; MixedJul 2027
ARO-INHBE
INHBE inhibitor (RNA interference)
INHBEPhase 1ObesityOct 2027
ARO-033–Phase 1Age-related Macular DegenerationJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06347003PlozasiranPhase 3Severe HypertriglyceridemiaMetabolic and endocrineJun 2026
NCT06347016PlozasiranPhase 3Severe HypertriglyceridemiaMetabolic and endocrineJun 2026
NCT06672445ARO-ATXN2 InjectionPhase 1Spinocerebellar Ataxia Type 2NeurologyDec 2026
NCT06937203ARO-ALK7Phase 1ObesityMetabolic and endocrineFeb 2027
NCT07221344ARO-MAPT-SCPhase 1Alzheimer DiseaseNeurologyJun 2027
NCT07223658ARO-DIMERPAPhase 1Hyperlipidemia; MixedMetabolic and endocrineJul 2027
NCT07037771ZodasiranPhase 3Homozygous Familial HypercholesterolemiaMetabolic and endocrineAug 2027
NCT06700538ARO-INHBEPhase 1ObesityMetabolic and endocrineOct 2027
NCT07241546ARO-RAGEPhase 2AsthmaRespiratoryDec 2027
NCT07662096ARO-033Phase 1Age-related Macular DegenerationOphthalmologyJul 2028
NCT06822790PlozasiranPhase 3HypertriglyceridemiaMetabolic and endocrineJul 2028
NCT07473843ZodasiranPhase 3Homozygous Familial HypercholesterolemiaMetabolic and endocrineJul 2028
NCT06880770PlozasiranPhase 3Severe HypertriglyceridemiaMetabolic and endocrineMar 2029

From the company's SEC filings

Cash and short-term investments of $1.6bn on 2026-06-30; operating cash outflow about $107m a year; runway about 180 months at that burn, to Jun 2041; 5 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

INHBE (1) ALK7 (1) APOC3 (1) AGER (1) MAPT (1) ANGPTL3 (1) APOB (1) ATXN2 (1)

Companies with the same targets

Eli Lilly Ionis Pharmaceuticals Fujian Shengdi Pharmaceutical Cantex Pharmaceuticals Eli Radiopharma Bristol-Myers Squibb Roche Voyager Therapeutics Amyloid Solution Nuravax

Companies built like this

Amylyx Pharmaceuticals Ionis Pharmaceuticals Beijing Suncadia Pharmaceuticals BioMarin Pharmaceutical MBX Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.